CurrentBody has successfully acquired Tria Beauty. In 2003, the inventors of LightSheer™, a leading in-clinic laser hair removal technology, aimed to revolutionize at-home hair removal by creating a handheld laser…
NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for…
Galderma has announced new Phase III data from the READY-4 clinical trial, showcasing the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess™) for treating frown lines and crow’s feet after repeated…
The World Health Organization reports that breast cancer was the most commonly diagnosed cancer among women in 157 out of 185 countries in 2022. That year, 2.3 million women were…
PSI Engineering is set to implement new outbound conveyor automation at Cardinal Health at-Home Solutions’ distribution centers. Serving approximately 5 million U.S. customers each year, Cardinal Health at-Home Solutions delivers…
CVS Health (NYSE: CVS) has named David Joyner as President and Chief Executive Officer, effective October 17, succeeding Karen Lynch, who stepped down in agreement with the Board of Directors.…
Aetna, a CVS Health company (NYSE: CVS), has introduced SimplePay Health, a new health plan tailored for self-insured clients. This plan aims to reduce costs, enhance health outcomes, and streamline…
DIA, a global non-profit organization for life sciences professionals, will host discussions on Canada’s precision regulation initiatives, the enhancement of its clinical trial infrastructure, and international collaboration at the Canada…
Nordic Pharma, Inc., a subsidiary of Nordic Group BV, introduced LACRIFILL Canalicular Gel, an innovative therapy for dry eye, in the U.S. this April and is showcasing it to leading…
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced positive results from the second Phase…
Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the…
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, have announced a clinical development collaboration. The partnership will evaluate the investigational tyrosine kinase…
